I.A. Bento, K.S.F. e Silva, K.K.V.O. Moura, C.L. Ribeiro Júnior, I.R. da Costa
Published: April 30, 2019
Genet. Mol. Res. 18(2): GMR18199
DOI: https://doi.org/10.4238/gmr18199

Cite this Article:
I.A. Bento, K.S.Fe Silva, K.K.V.O. Moura, C.L.Ribeiro Júnior, I.R. da Costa (2019). CYP2C19*3 polymorphism in patients with endometriosis. Genet. Mol. Res. 18(2): GMR18199. https://doi.org/10.4238/gmr18199

About the Authors
I.A. Bento, K.S.F. e Silva, K.K.V.O. Moura, C.L. Ribeiro Júnior, I.R. da Costa

Corresponding Author
K.S.F. e Silva
Email: smallbinho@hotmail.com

ABSTRACT

Endometriosis is a pathology that affects women in Brazil and around the world. It is characterized by the presence of endometrial cells outside the uterine cavity, leading to chronic pain, infertility and hormonal cycle deregulations. Ectopic endometrial foci may be responsible for changes in anatomy, in hormonal metabolism, immune and inflammatory systems and the pelvic peritoneum, causing pain and infertility. CYP2C19 is an important gene of the cytochrome p450 family that encodes an aromatase associated with estrogen metabolism. The CYP2C19*3 polymorphism is related to a higher susceptibility for endometriosis in women. This gene is overexpressed in chronic inflammation. The CYP2C19 gene is associated with drug metabolism, detoxification of potential carcinogenic agents and steroid metabolism . We analyzed the prevalence of the CYP2C19*3 polymorphism in women with endometriosis. The control group comprised 14 health women and the case group 19 patients with endometriosis. We found that the CYP2C19*3 polymorphism at a significantly higher rate in  endometriosis patients. No individual in the control group presented had this polymorphism and we found no association between this polymorphism and any social habits in patients with endometriosis.

Key words: CYP2C19*3, Endometriosis, Polymorphism, Steroid.